References of "Geboes, K"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on intestinal mucosal gene expression of endothelial cell adhesion molecules in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5 Suppl I), -677

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailIntestinal mucosal expression of matrix metalloproteinase and ADAM genes in patients with inflammatory bowel disease and the impact of infliximab therapy
Arijs, Ingrid; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5), 677

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailColonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatmen
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Acta Gastro-Enterologica Belgica (2009)

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Arijs, I.; Li, K.; Toedter, G. et al

in Gut (2009), 58(12), 1612-9

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti ... [more ▼]

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two cohorts of patients who received their first treatment with infliximab for refractory ulcerative colitis were studied. Response to infliximab was defined as endoscopic and histological healing. Total RNA from pre-treatment colonic mucosal biopsies was analysed with Affymetrix Human Genome U133 Plus 2.0 Arrays. Quantitative RT-PCR was used to confirm microarray data. RESULTS: For predicting response to infliximab treatment, pre-treatment colonic mucosal expression profiles were compared for responders and non-responders. Comparative analysis identified 179 differentially expressed probe sets in cohort A and 361 in cohort B with an overlap of 74 probe sets, representing 53 known genes, between both analyses. Comparative analysis of both cohorts combined, yielded 212 differentially expressed probe sets. The top five differentially expressed genes in a combined analysis of both cohorts were osteoprotegerin, stanniocalcin-1, prostaglandin-endoperoxide synthase 2, interleukin 13 receptor alpha 2 and interleukin 11. All proteins encoded by these genes are involved in the adaptive immune response. These markers separated responders from non-responders with 95% sensitivity and 85% specificity. CONCLUSION: Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-)response to infliximab. Further study of the pathways involved should allow a better understanding of the mechanisms of resistance to infliximab therapy in ulcerative colitis. ClinicalTrials.gov number, NCT00639821. [less ▲]

Detailed reference viewed: 10 (6 ULg)
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on colonic mucosal expression of barrier genes in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Van Lommel, L. et al

in Gastroenterology (2009), 136

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailColonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment.
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Journal of Crohn’s and Colitis [=JCC] (2009), 3(1), 3

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailTECK and MADCAM-1 mucosal expression in active IBD: the effect of infliximab therapy
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Gastroenterology (2009), 136

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on colonic mucosal expression of barrier genes in patients with inflammatory bowel disease.
Arijs, I.; Quintens, R.; Van Lommel, L. et al

in Acta Gastro-Enterologica Belgica (2009)

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailMucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment
Arijs, I.; De Hertogh, G.; Lemaire, K. et al

in PLoS ONE (2009), 4(11), 7984

Background: Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear ... [more ▼]

Background: Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect. We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD. Methodology/Principal Findings: Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4-6 weeks after their first infliximab infusion and in 12 control patients, using Affymetrix arrays. Quantitative real-time reverse-transcription PCR and immunohistochemistry were used to confirm microarray data. The dysregulation of many AMPs in colonic IBD in comparison with control colons was widely restored by infliximab therapy, and only DEFB1 expression remained significantly decreased after therapy in the colonic mucosa of IBD responders to infliximab. In ileal Crohn's disease (CD), expression of two neuropeptides with antimicrobial activity, PYY and CHGB, was significantly decreased before therapy compared to control ileums, and ileal PYY expression remained significantly decreased after therapy in CD responders. Expression of the downregulated AMPs before and after treatment (DEFB1 and PYY) correlated with villin 1 expression, a gut epithelial cell marker, indicating that the decrease is a consequence of epithelial damage. Conclusions/Significance: Our study shows that the dysregulation of AMPs in IBD mucosa is the consequence of inflammation, but may be responsible for perpetuation of inflammation due to ineffective clearance of microorganisms. [less ▲]

Detailed reference viewed: 23 (10 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Acta Gastro-Enterologica Belgica (2008)

Detailed reference viewed: 28 (14 ULg)
Full Text
Peer Reviewed
See detailGene expression of antimicrobial peptides in colonic mucosa of patients with inflammatory bowel disease before and after first infliximab treatment.
Arijs, I.; Lemaire, K.; Quintens, R. et al

in Gut (2008), 57(Suppl II), 102-103

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailLong-term outcome after infliximab for refractory ulcerative colitis
Ferrante, M.; Vermeire, S.; Fidder, H. et al

in Journal of Crohn’s and Colitis [=JCC] (2008), 2(3), 219-225

Background and aims: Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are tacking. We investigated long-term outcome including ... [more ▼]

Background and aims: Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are tacking. We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified. Methods: The first 121 outpatients (median age 38.0 years) with refractory UC treated with IFX were included. The primary outcome was colectomy-free survival. Secondary measures were sustained clinical response and serious adverse events. Results: From the 81 patients (67%) with an initial clinical response to IFX, 68% had a sustained clinical response. No independent predictors of sustained clinical response could be identified. Over a median (IQR) follow-up period of 33.0 (17.0-49.8) months, 21 patients (17%) came to colectomy. Independent predictors of colectomy were absence of short-term clinical response [Hazard ratio 10.8 (95% Cl 3.5-32.8), p < 0.001], a baseline CRP level >= 5 mg/L [Hazard ratio 14.5 (95% Cl 2.0-108.6), p=0.006] and previous IV treatment with corticosteroids and/or cyctosporine [Hazard ratio 2.4 (95% Cl 1.1-5.9), p=0.033]. Six patients developed a serious infection, three a malignancy, two a post-operative complication and one patient died (suicide). Conclusions: With a median follow-upof 33.0 months after start of IFX, 17% of patients with refractory UC needed colectomy, while sustained clinical response was present in 68% of initial responders. (c) 2008 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 72 (4 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Journal of Crohn’s and Colitis [=JCC] (2008), 2(1), 64

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease.
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Gastroenterology (2008), 134

Detailed reference viewed: 16 (11 ULg)
Full Text
Peer Reviewed
See detailEffect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Van Lommel, L. et al

in Gut (2008), 57(Suppl II), 39

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailMicroarray study of mucosal antimicrobial peptides in patients with inflammatory bowel disease before and after infliximab treatment.
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Journal of Crohn’s and Colitis [=JCC] (2008), 2(1), 60

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailGene expression profiling to predict the response of infliximab in patients with UC
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Journal of Crohn’s and Colitis [=JCC] (2007), 1(1), 34

Detailed reference viewed: 11 (5 ULg)
Full Text
Peer Reviewed
See detailMucosal gene expression profiling to predict response to infliximab in patients with ulcerative colitis
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Gut (2007), 56(Suppl III), 19

Detailed reference viewed: 7 (4 ULg)